Abstrakt

New insights in cardiotoxicity and heart failure.

Maydana Mariano, Echazarreta Diego, Ortiz Lucia, G?mez Matias, Portis Marcelo, Nunez Cristian

Myocardial dysfunction and the subsequent development of symptoms and signs of heart failure, which has been usually referred as cardiotoxicity, is one of the problems in cancer treatment therapies, that has raised highest concerns. Despite the different ways in which different drugs may cause myocardial damage, anthracyclines are drugs applied to most solid tumors and to patients with oncohematological pathologies, where the risk of developing heart failure can be as high as 48%.